Sinohealth Technology Holdings Limited
中康科技控股有限公司

(formerly known as Sinohealth Holdings Limited 中康控股有限公司)
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 2361)

PROFIT WARNING

This announcement is made by Sinohealth Technology Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Hong Kong Stock Exchange (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of all directors of the Company (the "**Board**") wishes to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the Group's latest unaudited consolidated management accounts for the six months ended 30 June 2026 ("**1H2026**") and the information currently available to the Board, it is expected that (i) the Group's revenue for 1H2026 will record a moderate increase to an estimated amount in the range of approximately RMB158.5 million to RMB164.5 million, as compared to approximately RMB147.9 million for the same period in 2025; and (ii) the net profit for 1H2026 will record a decrease to an estimated amount in the range of approximately RMB0.6 million to RMB6.6 million, as compared to approximately RMB24.5 million for the same period in 2025.

The Board considers that the expected decrease in profit was mainly attributable to (i)the impact of foreign exchange fluctuations, as the depreciation of USD against Renminbi during the period resulted in exchange losses arising from the Group's USD-denominated assets; and (ii) increased investment in research and development, including the recruitment of additional R&D talents and the development of AI-powered platforms to enhance the Group's long-term competitiveness.

Notwithstanding the expected decrease in profit, the Group's revenue for 1H2026 recorded a moderate increase as compared to the same period in 2025. The Group has continued to make progress in its strategic initiatives during the period, including the expansion of innovative data-driven business and the development of AI-powered platforms. The Group maintains a healthy financial position with sufficient cash reserves to support its operations and sustainable development. The Board considers that the above factors are transitional in nature and the Group remains confident in its long-term growth prospects.

As of the date of this announcement, the Company is currently finalizing the preparation of the interim results of the Group for 1H2026. The information as set out in this announcement is the Board's preliminary assessment according to the Group's unaudited consolidated management accounts and the information currently available to the Board. Such information has neither been audited and confirmed by the Company's independent auditors nor reviewed by the audit committee of the Company and is subject to adjustments. The Company's interim results announcement for 1H2026 will be published by the end of August 2026, in compliance with the Listing Rules. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for 1H2026.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Sinohealth Technology Holdings Limited
Wu Yushu
Chairman and executive Director

Hong Kong, 29 July 2026

As of the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Chui Hoi Yam and Mr. Wei Bin.